Trademark: 79307220
Word
ARVIDAL
Status Date
Monday, March 14, 2022
Filing Date
Friday, December 11, 2020
Published for Opposition
Tuesday, November 2, 2021
Abandoned Date
Monday, March 14, 2022
5 pharmaceutical preparations and pharmaceutical products for the prevention, and treatment of infections or diseases caused by viruses; pharmaceutical preparations and pharmaceutical products for the prevention, and treatment of infections or diseases caused by viruses, namely, by intravenous, intramuscular, oral, sublingual, buccal, nasal, topical administration and/or administered by inhalation, by spraying or by nebulisation in patients; pharmaceutical preparations and pharmaceutical products for the prevention, and treatment of infections caused by viruses, seasonal and pandemic influenza A and B viruses, seasonal coronaviruses being Alpha-, Beta-, Gamma- and Deltacoronaviruses, severe acute respiratory syndrome (SARS-CoV) coronaviruses and Middle East respiratory syndrome (MERS) coronavirus, adenoviruses, respiratory syncytial viruses, parainfluenza viruses, rhinoviruses, human metapneumoviruses, bocaviruses, and infections of combined etiology being multiple viral infections; pharmaceutical preparations and pharmaceutical products for the prevention, and treatment of infections caused by viral infections of the upper and lower respiratory tract; pharmaceutical preparations and pharmaceutical products for the prevention, and treatment of acute respiratory infections caused by viral infections of the upper and lower respiratory tract; pharmaceutical preparations and pharmaceutical products for the prevention and treatment of tissue lesions in the lungs caused by severe pulmonary infectious diseases; pharmaceutical preparations and pharmaceutical products for the prevention and treatment of complications arising from or caused by viral infections; pharmaceutical preparations and pharmaceutical products for the prevention and treatment of acute respiratory infections, acute respiratory viral infections of unknown origins and complications arising from or caused by viral infections
Apr 5, 2023
Final Decision Transaction Processed By Ib
Mar 14, 2023
Final Disposition Notice Sent To Ib
Mar 14, 2023
Final Disposition Notice Created, To Be Sent To Ib
Oct 31, 2022
Notification Of Possible Opposition - Processed By Ib
Oct 12, 2022
Notification Of Possible Opposition Sent To Ib
Oct 12, 2022
Notification Of Possible Opposition Created, To Be Sent To Ib
Mar 15, 2022
Abandonment Notice E-Mailed - Inter Partes Decision
Mar 14, 2022
Abandonment - After Inter Partes Decision
Mar 14, 2022
Opposition Terminated No. 999999
Mar 14, 2022
Opposition Sustained No. 999999
Dec 13, 2021
Refusal Processed By Ib
Nov 22, 2021
Opposition Instituted No. 999999
Nov 16, 2021
Opposition Notice (Ib Refusal) Sent To Ib
Nov 16, 2021
Opposition Notice (Ib Refusal) Created
Nov 15, 2021
Opposition Papers Received At Ttab
Nov 2, 2021
Official Gazette Publication Confirmation E-Mailed
Nov 2, 2021
Published For Opposition
Oct 13, 2021
Notification Of Notice Of Publication E-Mailed
Sep 28, 2021
Approved For Pub - Principal Register
Sep 27, 2021
Teas/Email Correspondence Entered
Sep 27, 2021
Correspondence Received In Law Office
Sep 27, 2021
Teas Response To Office Action Received
Jul 24, 2021
Refusal Processed By Ib
Jul 2, 2021
Non-Final Action Mailed - Refusal Sent To Ib
Jul 2, 2021
Refusal Processed By Mpu
Jul 2, 2021
Non-Final Action (Ib Refusal) Prepared For Review
Jul 1, 2021
Non-Final Action Written
Jun 24, 2021
Assigned To Examiner
Jun 4, 2021
Assigned To Examiner
Jun 3, 2021
Assigned To Examiner
May 13, 2021
Correction From The Ib Examined, No Action Is Needed
May 10, 2021
Correction Transaction Received From Ib
Apr 2, 2021
Application Filing Receipt Mailed
Mar 29, 2021
New Application Office Supplied Data Entered
Mar 25, 2021
Sn Assigned For Sect 66a Appl From Ib
Trademark Alertz updated from USPTO on 2030-01-24
